Teijin Limited

Teijin Pharma Limited

Hiroko Ogawa

Satoshi Sugiura

Yoshiyuki Matsumoto

Kenichi Masuda

Gen Unoki

Takaharu Tsutsumi

Kenichiro Takagi

Kazuyoshi Yamaoka

Yuri Sakai

Reiko Takarada

Toshihiro Ishii

Akira Nakano

Yoshinori Sugimoto

Susumu Yasuoka

Tetsuya Suga

Masahiro Koga

A compound having GSK-3 inhibitory activity.  Aand Aare a single bond, an aliphatic hydrocarbon group; Aand Aare a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; Gis a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; Gis H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; Ais a single bond, NR; Ris H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; Ais a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; Ris H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and Rmay be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when Ais CR&#x2550;CR or C&#x2261;C, wherein R is H or an lower aliphatic hydrocarbon group.

Substituted pyrrolo[3,2-d]pyrimidine derivatives

This invention provides a nucleic acid sequence encoding a trypsin-like enzyme which can be present at the trachea of human lungs, and can selectively digest a synthetic substrate for trypsin and a synthetic substrate for thrombin, and fibrinogen; and a process for producing the trypsin-like enzyme by genetic engineering utilizing the nucleic acid sequence.

Nucleic acid sequence encoding trypsin-like enzyme and process for

Growing community of inventors

Hino, Japan

Hiroko Ogawa